Stem Cells Without Ethical Implications Are Ready for the Spotlight
Induced Pluripotent Stem Cells Forming an Emerging Market
June 15, 2020
The global market for induced pluripotent stem cells (iPSCs), should reach $3.8 billion, growing 9.2% annually, according to the latest report by BCC Research, Induced Pluripotent Stem Cells: Global Markets.
iPSCs are reprogrammed cells from a patient’s body, and are not harvested from embryos, thus avoiding the ethical debates associated with embryonic stem cells. Like other stem cells, they hold the immense promise of transforming into various types of human tissue cells, and potentially representing highly effective treatments for serious illnesses.
Report Highlights
- Advances in genetics such as NGS technologies have promoted the progress of precision medicine, where the availability of iPSCs from a variety of genetic, lifestyle and environment backgrounds will help make precision healthcare a clinical reality.
- As of December of 2019, several iPSCs clinical trials have launched or have planned to launch soon. These clinical trials have covered various diseases—ischemic heart disease, Parkinson’s Disease, spinal cord injuries, cornea repair and some advanced solid tumors.
- Cellular reprogramming, including iPSC technology, was awarded the 2012 Nobel Prize.
Read the full report here: https://www.bccresearch.com/market-research/biotechnology/induced-pluripotent-stem-cells-report.html
“As a breakthrough technology recognized by the Nobel Prize in Physiology or Medicine 2012, iPSCs technology has brought a revolutionary change to modern medicine,” write BCC Research analysts. “iPSC-related products are forming an emerging market despite the fact that clinical applications are still at their early stage. The potential scope of the iPSC market is becoming clear.”
About BCC Research
BCC Research publishes market research reports that provide organizations with intelligence to drive smart business decisions. By partnering with industry experts worldwide, BCC Research provides unbiased measurements and assessments of global markets covering current and emerging industrial and technology sectors. For more information about BCC Research, visit bccresearch.com.
Induced Pluripotent Stem Cells: Global Markets( BIO135C )
Publish Date: Jan 2020
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
- Global Botanical and Plant-Derived Drug Market Projected to Hit $58.1 Billion by 2030
- Global Protein Expression Market Poised for 10.9% CAGR Expansion by 2030
- BCC Research Forecasts 7.5% CAGR for Global Biological Cancer Therapies Market
- Fusion Proteins Market to Hit $64.9 Billion by 2030
Reports from Cell Biology
- Global DNA Read, Write, and Edit Market
- Validation, Calibration, and Standardization in the Life Sciences Market
- Cloud Computing in Cell Biology, Genomics and Drug Development: Global Markets
- Decentralized Clinical Trials: Global Markets
- Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
Recent News
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast